Genentech takes the health and safety of our patients, customers, employees, and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more information, please visit our COVID-19 response page.
We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more
The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.
Emicizumab prophylaxis for the treatment of people with moderate or mild hemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study
Hermans C, Negrier C, Lehle M, et al. ISTH 2022. Oral presentation 30.5.
Analysis of F8 genotypes and pharmacodynamic and safety biomarkers in people with moderate or mild hemophilia A receiving emicizumab in the HAVEN 6 trial
Kiialainen A, Negrier C, Pipe SW, et al. ISTH 2022. Poster presentation 0671.
Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II
Improvement in annualized bleed rate in patients with hemophilia A initiating emicizumab – physician reported outcomes from the Adelphi Hemophilia A Disease Specific Programme
Khairnar R, Decker-Palmer M, Mellor J, et al. ASH 2021; Poster presentation 1961.
Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: An updated summary of thrombotic events and thrombotic microangiopathies
Howard M, McKinley D, Sanabria F, et al. ASH 2021; Poster presentation 3186.
Emicizumab prophylaxis in persons with hemophilia A, aged ≥50 years, with comorbidities – pooled data from four phase III studies (HAVEN 1, 3, and 4, and STASEY)
Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. ASH 2021; Poster presentation 2103.
Emicizumab prophylaxis in people with mild or moderate haemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 6 study
Negrier C, Mahlangu J, Lehle M, et al. EAHAD 2022. Oral presentation OR002.
Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 study
Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors
Emicizumab prophylaxis in people with haemophilia A (PwHA), aged ≥50 years, with comorbidities – Pooled data from four phase III studies (HAVEN 1, 3, and 4, and STASEY)
Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. EAHAD 2022. Poster presentation PO053.
Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis
Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: Pooled data from four HAVEN studies
Callaghan M, Negrier C, Paz-Priel I, et al. Oral presentation OC 60.2.
Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 HAVEN 3 study experience
Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation P-2395.
Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study
Kiialainen A, Petry C, Jiménez-Yuste V, et al. Poster presentation PB0942.
A phase IV, multicenter, open-label study of emicizumab prophylaxis in persons with hemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
Escobar M, Dunn A, Quon D, et al. Poster presentation 1786.
A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): Interim analysis results
Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study
A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)
Wang S, Zhao X, Wang X, et al. Poster presentation PB0957.
Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.
Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies
Skinner M, Negrier C, Paz-Priel I, et al. Poster presentation PB0698.
Factor VIII use in the treatment of breakthrough bleeds in persons with hemophilia A without inhibitors on emicizumab prophylaxis: The phase III HAVEN 3 study experience
Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation.